Open Forum Infect Dis . COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020

[tetano]

Open Forum Infect Dis


. 2020 Nov 9;7(11):ofaa528.
doi: 10.1093/ofid/ofaa528. eCollection 2020 Nov.
COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020


Anna M Acosta ¹ , Adria L Mathis ^{1 2} , Daniel S Budnitz ^{1 3} , Andrew I Geller ^{1 3} , Shua J Chai ^{3 4 5} , Nisha B Alden ⁶ , James Meek ⁷ , Evan J Anderson ^{8 9 10} , Patricia Ryan ¹¹ , Sue Kim ¹² , Kathryn Como-Sabetti ¹³ , Salina Torres ¹⁴ , Elizabeth Dufort ¹⁵ , Nancy M Bennett ¹⁶ , Laurie M Billing ¹⁷ , Melissa Sutton ¹⁸ , H Keipp Talbot ¹⁹ , Andrea George ²⁰ , Huong Pham ¹ , Aron J Hall ¹ , Alicia Fry ^{1 3} , Shikha Garg ^{1 3} , Lindsay Kim ^{1 3}



Affiliations

• PMID: 33274249
• PMCID: PMC7686662 (available on 2021-11-09)
• DOI: 10.1093/ofid/ofaa528

Abstract

Using a coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1-June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.

Keywords: coronavirus; hospitalization; therapeutics.